RedCarpetLife
Billionaires
Business
Luxury Lifestyle
Lists
World Leaders
Fashion & Style
Tools
Featured Articles
Learn Finance with Arthalogy
Advertise with RedCarpetLife
Contact Us
Careers at RedCarpetLife
Meet Our Authors
About Us
Correction or Feedback
Terms of Use
Privacy Policy
3316
In the world , as of 16 Mar 2026
Rao Wei

Rao Wei

R. Wei
$1.03 B ₹ 9,717 Cr
Real Time Net Worth #3316 Ranking as of 16 Mar 2026 By Forbes
Check Your Ranking

More on Rao Wei

Gender

Male

Age

62Y

Country

China

Born On

January, 1964

Deceased

No

Relationship Status

Unknown

Children

Unknown

Education

Unknown

Designation Info :

Self-Made

Yes

Entrepreneur Type

Self-Made (Healthcare)

Primary Organization

Shenzhen New Industries Biomedical Engineering

Titles

Chairman

Sources of Wealth

Medical Equipment

Industry

Healthcare, Medical Devices

About Rao Wei

R ao Wei is the chairman of Shenzhen New Industries Biomedical Engineering (Snibe), a pioneering Chinese company in the field of clinical laboratory instruments and in vitro diagnostics (IVD). He joined the company in 1997, when it was a small trading firm, and led its transformation into a research-driven manufacturer. Snibe was the first company in China to receive FDA clearance for a chemiluminescence immunoassay (CLIA) analyzer.

Under Rao's leadership, Snibe has expanded its global footprint, exporting its diagnostic products to over 140 countries. The company successfully listed on the Shenzhen Stock Exchange in 2020. Rao's focus on technological innovation in the medical diagnostics space has not only generated significant wealth but also positioned Snibe as a key competitor to Western giants in the global healthcare market.

Advertisement

Quick Reads

Early Life and Background

Rao Wei is a Chinese businessman, the Chairman of Shenzhen New Industries Biomedical Engineering (SZSE: 300832), a major supplier of clinical laboratory instruments.

In 1997, at age 33, Rao joined New Industries Biomedical Engineering when it was a trading company with only a dozen people. The company went public on the Shenzhen Stock Exchange in 2020, raising $192 million for R&D and manufacturing.

  • Core Company: Shenzhen New Industries Biomedical Engineering (Clinical laboratory instruments).
  • Founding: Joined in 1997 when it was a trading company with a dozen people.
  • IPO Funds: Raised $192 million in 2020 for R&D and manufacturing.

Career Journey of Rao Wei

Rao Wei's career is defined by his successful leadership in transforming a small trading company into a publicly traded biomedical enterprise. His structural achievement is tied to advancing the company’s focus to manufacturing and supplying complex clinical laboratory instruments.

The company's 2020 IPO secured his wealth and demonstrated the demand for domestic innovation in the Chinese healthcare technology sector. The funds raised, $192 million, were explicitly designated for R&D and manufacturing expansion.

Advertisement

Rao Wei's Timeline

1997 (Age 33):

Joined New Industries Biomedical Engineering when it was a small trading company.

2020:

Shenzhen New Industries executes its IPO on the Shenzhen Stock Exchange, raising $192 million.

Ongoing:

Continues as Chairman.

Major Business Ventures and Investments

Rao Wei's wealth is concentrated in his controlling stake and continued leadership of the publicly traded healthcare technology giant, Shenzhen New Industries Biomedical Engineering.

  • Shenzhen New Industries (SZSE: 300832): Chairman of the supplier of clinical laboratory instruments.
  • IPO: Listed on the Shenzhen Stock Exchange in 2020.
  • Sector Focus: Healthcare technology, diagnostics, and laboratory instruments.

Advertisement

Philanthropy and Social Impact

Fashion, Style, and Lifestyle

Advertisement

Quotes and Philosophy

No publicly available quotes.

Fun Facts & Trivia

  • He chairs Shenzhen New Industries Biomedical Engineering, a supplier of clinical laboratory instruments.
  • In 1997, he joined the company when it was a trading company with only a dozen people.
  • The company's 2020 IPO raised $192 million for R&D and manufacturing.

Advertisement

More Profiles

Sofie Kirk Kristiansen

Sofie Kirk Kristiansen

#446

-0.01% | -$0.38M

Dmitri Bukhman

Dmitri Bukhman

#231

+0.01% | +$1.49M

You May Like

Sources & References

This profile is compiled from verified biographical and financial records:

  • Wealth Data: Real-time tracking and historical data from Forbes Billionaires and the Bloomberg Billionaires Index.
  • Biographical Records: Educational and career history sourced from Reuters, The Wall Street Journal, and official university alumni directories.
  • Regulatory Filings: Shareholder and executive disclosures from stock exchange databases, including HKEX, SSE, SZSE, and SEC EDGAR.
  • Corporate History: Primary data from annual company reports, founding charters, and verified press announcements.

All information is cross-referenced with public sources for accuracy; some narrative sections are AI-assisted summaries.

If you find any inaccuracies, please report them to admin@redcarpetlife.in

Sponsored Content